2016
A high-throughput nanofibers mat-based micro-solid phase extraction for the determination of cationic dyes in wastewater
Qi F, Qian L, Liu J, Li X, Lu L, Xu Q. A high-throughput nanofibers mat-based micro-solid phase extraction for the determination of cationic dyes in wastewater. Journal Of Chromatography A 2016, 1460: 24-32. PMID: 27435684, DOI: 10.1016/j.chroma.2016.07.020.Peer-Reviewed Original ResearchConceptsLimit of detectionCationic dyesNanofiber matsMicro-solid phase extractionDyeing industry wastewaterHigh-throughput sample preparation techniqueShorter extraction timeDischarge standardsIndustry wastewaterAdsorption capacityWater pollutantsPlate formatHigh-throughput sample preparation procedureBest extraction efficiencyWastewaterSample preparation techniquesExtraction timeMicro-SPEExtraction efficiencyDyePreparation techniquesPolypyrroleTextile industryPreparation procedureOptimal conditions
2012
Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib
Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, Fabris L, Fiorotto R, Strazzabosco M. Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib. Hepatology 2012, 56: 2363-2374. PMID: 22653837, PMCID: PMC3460040, DOI: 10.1002/hep.25872.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, HormonalBenzenesulfonatesBile DuctsCaspase 3Cell ProliferationCells, CulturedCyclic AMP-Dependent Protein KinasesCystsDrug Therapy, CombinationEpithelial CellsKi-67 AntigenLiver DiseasesMAP Kinase Signaling SystemMiceMice, KnockoutNiacinamideOctreotidePhenylurea CompoundsPhosphorylationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-rafPyridinesSorafenibTRPP Cation ChannelsConceptsRaf-1Cell proliferationB-RafPhosphorylated ERKRaf kinase activitySignal-regulated kinase 1/2 pathwayRAF inhibitorsCyclic adenosine monophosphateRaf/MEK/ERKCyst growthDefective miceKinase 1/2 pathwayParadoxical activationCAMP/PKAMEK/ERKPolycystin-2Kinase AKinase activityWT cellsDependent activationERK1/2 phosphorylationInhibitor 14Epithelial cellsAdenosine monophosphateERK
2011
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
Cao M, Xu Y, Youn J, Cabrera R, Zhang X, Gabrilovich D, Nelson D, Liu C. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Laboratory Investigation 2011, 91: 598-608. PMID: 21321535, PMCID: PMC3711234, DOI: 10.1038/labinvest.2010.205.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzenesulfonatesBone Marrow CellsCarcinoma, HepatocellularCell DivisionCell Line, TumorDisease ProgressionImmunity, CellularLiver NeoplasmsMiceMice, Inbred BALB CMyeloid CellsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsPyridinesSorafenibSpleenT-Lymphocytes, RegulatoryConceptsMyeloid-derived suppressor cellsImmunosuppressive cell populationsAnti-tumor immunityTumor-bearing hostsImmune cell populationsLiver cancer modelMurine liver cancer modelHepatocellular carcinomaCell populationsCancer modelNovel multi-kinase inhibitorSuppressive immune cell populationBALB/c miceDepletion of TregsImpact of sorafenibRegulatory T cellsAdvanced hepatocellular carcinomaTreatment of sorafenibKinase inhibitor sorafenibMulti-kinase inhibitorHCC cell growthSuppressor cellsTumor burdenC miceCancer patientsAnti-Adrenergic Medications and Edema Development after Intracerebral Hemorrhage
Sansing LH, Messe SR, Cucchiara BL, Lyden PD, Kasner SE. Anti-Adrenergic Medications and Edema Development after Intracerebral Hemorrhage. Neurocritical Care 2011, 14: 395-400. PMID: 21264527, DOI: 10.1007/s12028-010-9498-z.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-AntagonistsAgedAntihypertensive AgentsAntioxidantsBenzenesulfonatesBlood PressureBrain EdemaCerebral HemorrhageClonidineCohort StudiesCritical CareDouble-Blind MethodDrug Therapy, CombinationFemaleFree Radical ScavengersGlasgow Coma ScaleHumansMaleMiddle AgedMultivariate AnalysisProspective StudiesTreatment OutcomeConceptsIntracerebral hemorrhageClinical outcomesBlood pressure medication useAcute intracerebral hemorrhageSympathetic nervous systemAdrenergic medicationsAntihypertensive medicationsAntihypertensive treatmentMethodsThe patientsPlacebo armBlood pressureMedication useEdema volumePerihematomal edemaEdema developmentInflammatory responseLess edemaHemorrhage volumeAdrenergic activationMedicationsNervous systemMultivariate analysisEdemaHemorrhagePatients
2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy
Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy. BJU International 2010, 106: 772-778. PMID: 20230385, DOI: 10.1111/j.1464-410x.2010.09218.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, NeoplasmAntineoplastic AgentsBenzenesulfonatesCarbonic Anhydrase IXCarbonic AnhydrasesCarcinoma, Renal CellEpidemiologic MethodsFemaleHumansImmunohistochemistryIndolesKidney NeoplasmsMaleMiddle AgedNeoplasm ProteinsNiacinamidePhenylurea CompoundsPrognosisPyridinesPyrrolesSorafenibSunitinibTreatment OutcomeVascular Endothelial Growth Factor AConceptsMetastatic clear-cell renal cell carcinomaVEGF-targeted therapyCarbonic anhydrase IXClear-cell renal cell carcinomaClear-cell componentRenal cell carcinomaTumor shrinkageCell carcinomaClear-cellTreated with vascular endothelial growth factor (VEGF)-targeted therapyVascular endothelial growth factor (VEGF)-targeted therapyVascular endothelial growth factor-targeted therapyAssociated with greater tumor shrinkageCarbonic anhydrase IX expressionResponse to sorafenib treatmentSunitinib-treated patientsResponse to sunitinibSorafenib-treated patientsPredictors of outcomeSunitinib treatmentSorafenib treatmentPrimary endpointPredictive biomarkersPrognostic valueCAIX expressionVerification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines
Boonstra J, van Marion R, Beer D, Lin L, Chaves P, Ribeiro C, Pereira A, Roque L, Darnton S, Altorki N, Schrump D, Klimstra D, Tang L, Eshleman J, Alvarez H, Shimada Y, van Dekken H, Tilanus H, Dinjens W. Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines. Journal Of The National Cancer Institute 2010, 102: 271-274. PMID: 20075370, PMCID: PMC2902814, DOI: 10.1093/jnci/djp499.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic AgentsBenzenesulfonatesBiomedical ResearchCarcinomaCarcinoma, Large CellCell Line, TumorClinical Trials as TopicColorectal NeoplasmsDNA FingerprintingEsophageal NeoplasmsHumansLung NeoplasmsNational Institutes of Health (U.S.)NiacinamideOligonucleotidesOligopeptidesPhenylurea CompoundsProtein Kinase InhibitorsPyridinesSorafenibStomach NeoplasmsTandem Repeat SequencesTelomeraseUnited StatesConceptsEsophageal adenocarcinomaCell linesTumor typesHuman esophageal adenocarcinoma cell lineEsophageal adenocarcinoma cell linesEsophageal adenocarcinoma patientsDevelopment of treatment strategiesAdenocarcinoma cell lineBIC-1Treatment strategiesSEG-1Clinical trialsTumorCancer researchContaminated cell linesNational InstituteCellsExperimental cancer research
2009
A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension
Gomberg‐Maitland M, Maitland M, Barst R, Sugeng L, Coslet S, Perrino T, Bond L, LaCouture M, Archer S, Ratain M. A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension. Clinical Pharmacology & Therapeutics 2009, 87: 303-310. PMID: 20010555, PMCID: PMC3291104, DOI: 10.1038/clpt.2009.217.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionInhibitor sorafenibArterial hypertensionPulmonary arterial hypertension patientsAdministered to cancer patientsSafety of sorafenibMultikinase inhibitor sorafenibActivity of sorafenibOpen-label trialModerate skin reactionsDose escalationStable diseaseParenteral prostanoidsDosing regimenSingle-centerAdverse eventsPhase IbSorafenibClinical evaluationCancer patientsSkin reactionsFunction testsPatientsAnticancer agentsTherapeutic activityPrognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C, Eigl B, Ruether J, Cheng T, North S, Venner P, Knox J, N. K, Kollmannsberger C, McDermott D, Oh W, Atkins M, Bukowski R, Rini B, Choueiri T. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. Journal Of Clinical Oncology 2009, 27: 5794-5799. PMID: 19826129, DOI: 10.1200/jco.2008.21.4809.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Renal CellFemaleHumansIndolesKidney NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsPrognosisPyridinesPyrrolesSorafenibSunitinibSurvival RateVascular Endothelial Growth Factor AConceptsMetastatic renal cell carcinomaMemorial Sloan-Kettering Cancer CenterRenal cell carcinomaMedian OSAdverse prognostic factorOverall survivalPrognostic factorsVascular endothelial growth factorCell carcinomaMemorial Sloan-Kettering Cancer Center modelVascular endothelial growth factor-targeted agentGrowth factor-targeted agentsIndependent adverse prognostic factorTreated with vascular endothelial growth factorCancer CenterPredictor of shorter survivalFavorable-risk groupVEGF-targeted agentsPoor-risk groupTreated with sunitinibIntermediate-risk groupMedian Follow-UpCox proportional hazards regressionKarnofsky performance statusCanadian cancer centersC-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas. Clinical Cancer Research 2009, 15: 5704-5713. PMID: 19737955, PMCID: PMC2763114, DOI: 10.1158/1078-0432.ccr-09-0198.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBenzenesulfonatesCell Line, TumorCell ProliferationCell SurvivalCohort StudiesDisease ProgressionFemaleGene SilencingHumansIndolesMaleMelanomaMiddle AgedNevusNiacinamidePhenolsPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins c-rafPyridinesRNA, Small InterferingSensitivity and SpecificitySkin NeoplasmsSorafenibYoung AdultConceptsExtracellular signal-regulated kinaseC-RafC-Raf expressionSubset of melanomasPhospho-c-RafSignal-regulated kinaseCell linesProtein kinase inhibitionMitogen-activated protein kinase inhibitionDecreased viabilityDecreased Bcl-2 expressionProtein kinaseCell signalingBcl-2 inhibitionRaf kinaseB-RafMelanoma cell linesPhospho-MEKSpecific siRNAsSitu protein expressionGW5074Major isoformsKinasePhospho-ERKBcl-2 expressionExpression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research 2009, 15: 1076-1085. PMID: 19188183, PMCID: PMC4263281, DOI: 10.1158/1078-0432.ccr-08-2280.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBenzenesulfonatesCarboplatinCell Line, TumorDisease-Free SurvivalDrug Delivery SystemsHumansMelanomaMitogen-Activated Protein Kinase 3NiacinamidePaclitaxelPhenylurea CompoundsPyridinesReceptors, Vascular Endothelial Growth FactorSkin NeoplasmsSorafenibTreatment OutcomeConceptsSerine/threonine-protein kinase 1Mitogen-activated protein kinase pathwayHigher ERK1/2Protein kinase 1Fibroblast growth factor receptor 1Protein kinase pathwayReceptor tyrosine kinasesPlatelet-derived growth factor receptor betaGrowth factor receptor betaVEGF-R2 expressionSorafenib targetsB-RAF V600E mutationGrowth factor receptor 1C-RafKinase pathwayVascular endothelial growth factor receptor 2B-RafKinase 1Kinase 1/2Tyrosine kinaseEndothelial growth factor receptor 2Factor receptor 1ERK1/2Kinase inhibitorsMultitarget kinase inhibitor
2008
Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation. Clinical Cancer Research 2008, 14: 5385-5399. PMID: 18765530, PMCID: PMC2561272, DOI: 10.1158/1078-0432.ccr-08-0469.Peer-Reviewed Original ResearchConceptsPancreatic adenocarcinoma cellsLong-term colony formation assaysCaspase-8C-FLIPExtracellular signal-regulated kinase 1/2Full-length BidSignal-regulated kinase 1/2Activation of BaxKnockdown of CD95Multiple antiapoptotic proteinsExpression of BimColony formation assaysAdenocarcinoma cellsVorinostat treatmentCD95 activationKill tumor cellsProapoptotic signalsProtease pathwayKinase 1/2Caspase-9Cathepsin proteasesAntiapoptotic proteinsBcl-xLFADD expressionMcl-1Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Chia S, Senatore F, Raffel O, Lee H, Wackers F, Jang I. Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. JACC Cardiovascular Interventions 2008, 1: 415-423. PMID: 19463339, DOI: 10.1016/j.jcin.2008.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesBiomarkersCardiovascular AgentsCoronary AngiographyCreatine Kinase, MB FormDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumPiperazinesPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentStroke VolumeTime FactorsTomography, Emission-Computed, Single-PhotonTreatment OutcomeTroponin ITroponin TUnited StatesVentricular Function, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIElevation myocardial infarctionPercutaneous coronary interventionInfarct sizeClinical outcomesMyocardial infarctionCardiac biomarkersCoronary interventionCreatine kinaseCK-MBLarge ST-segment elevation myocardial infarctionTroponin TIntracellular calcium modulatorsLarger infarct sizeVentricular ejection fractionCardiac biomarker levelsLeft ventricular functionComposite clinical eventsTime-concentration curveEVOLVE trialLower LVEFAdverse eventsEjection fractionTargeted Therapy in Advanced Non-Small-Cell Lung Cancer
Gettinger S. Targeted Therapy in Advanced Non-Small-Cell Lung Cancer. Seminars In Respiratory And Critical Care Medicine 2008, 29: 291-301. PMID: 18506667, DOI: 10.1055/s-2008-1076749.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Non-Small-Cell LungDrug Delivery SystemsEpidermal Growth FactorErlotinib HydrochlorideHumansIndolesLung NeoplasmsNiacinamidePhenylurea CompoundsPiperidinesProtein Kinase InhibitorsPyridinesPyrrolesQuinazolinesSignal TransductionSorafenibSunitinibTreatment OutcomeVascular Endothelial Growth Factor AConceptsPhase II trialLung cancerEpidermal growth factor receptorII trialEGFR inhibitorsSmall molecule inhibitorsAdvanced non-small cell lung cancerNon-small cell lung cancerStandard first-line chemotherapyVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayCancer cell pathwaysStandard salvage chemotherapyFirst-line chemotherapyPhase III studyPhase III trialsCell lung cancerSignificant survival advantageEGFR gene mutationsLeast equivalent activityVEGF receptor tyrosine kinasesCancer cell proliferationGrowth factor pathwaysGrowth factor receptorSalvage chemotherapy
2007
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
Jang I, Weissman N, Picard M, Zile M, Pettigrew V, Shen S, Tatsuno J, Hibberd M, Tzivoni D, Wackers F, Investigators T. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). American Heart Journal 2007, 155: 113.e1-113.e8. PMID: 18082500, DOI: 10.1016/j.ahj.2007.08.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesCardiac CatheterizationCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleElectrocardiographyFemaleFollow-Up StudiesHumansInfusions, IntravenousMaleMiddle AgedMyocardial InfarctionPiperazinesProbabilityReference ValuesRisk AssessmentSalvage TherapyStroke VolumeSurvival RateTreatment OutcomeVentricular Function, LeftConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionST-elevation myocardial infarctionPrimary PCIMCC-135Percutaneous coronary interventionAcute myocardial infarctionInfarct sizeMyocardial infarctionDay 5Coronary interventionClinical outcomesCalcium overloadPreservation of LVEFAcute ST-elevation myocardial infarctionEnd pointTarget populationComposite clinical outcomeLeft Ventricular SalvagePlacebo-controlled studyPrimary end pointSecondary end pointsLow-dose groupVentricular ejection fractionHigh-dose group
2006
Toxicities of Antiangiogenic Therapy in Non–Small-Cell Lung Cancer
Herbst RS. Toxicities of Antiangiogenic Therapy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2006, 8: s23-s30. PMID: 17239287, DOI: 10.3816/clc.2006.s.010.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHumansIndolesLung NeoplasmsNiacinamidePhenylurea CompoundsPiperidinesPyridinesPyrrolesQuinazolinesSorafenibSunitinibVascular Endothelial Growth FactorsConceptsAnti-VEGF antibodyCell lung cancerVascular endothelial growth factorAntiangiogenic agentsOverall survivalLung cancerPhase III pivotal trialsClass-effect toxicitiesFirst-line chemotherapyAdverse event profileSquamous cell histologyChemotherapy-associated toxicityVEGFR tyrosine kinaseTyrosine kinase inhibitorsEndothelial growth factorMetastatic NSCLCThromboembolic eventsCell histologyPivotal trialsEvent profileRisk factorsVEGF receptor activityAntiangiogenic therapySmall molecule inhibitorsTumor types
2005
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study
Jang I, Pettigrew V, Picard M, Kowey P, Demmel V, Zile M, Tatsuno J, Wackers F, Hibberd M. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study. Journal Of Thrombosis And Thrombolysis 2005, 20: 147-153. PMID: 16261287, DOI: 10.1007/s11239-005-3267-4.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAngioplasty, Balloon, CoronaryBenzenesulfonatesCalciumDouble-Blind MethodEchocardiographyHumansMaleMiddle AgedMuscle CellsMyocardial InfarctionMyocardial Reperfusion InjuryNecrosisPiperazinesRadiographyTomography, Emission-Computed, Single-PhotonVentricular Function, LeftConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionLeft Ventricular SalvageElevation myocardial infarctionPlacebo-controlled clinical trialMCC-135Percutaneous coronary interventionIntracellular calcium overloadMyocardial infarctionPost-myocardial infarctionVentricular functionCalcium overloadEVOLVE studyCoronary interventionAdjunct therapyInfarct sizeClinical trialsPrimary PCIAcute ST-elevation myocardial infarctionMI studiesVentricular ejection fractionSerum cardiac markersAcute myocardial infarctionEarly clinical studiesMyocardial infarction sizeFiberoptic Endoscopic Evaluation of Swallowing (FEES) with and without Blue-Dyed Food
Leder S, Acton L, Lisitano H, Murray J. Fiberoptic Endoscopic Evaluation of Swallowing (FEES) with and without Blue-Dyed Food. Dysphagia 2005, 20: 157-162. PMID: 16172826, DOI: 10.1007/s00455-005-0009-x.Peer-Reviewed Original ResearchConceptsFiberoptic endoscopic evaluationTrue vocal foldsPharyngeal swallowFEES resultsEndoscopic evaluationPharyngeal dysphagiaVocal foldsKappa valuesFood trialsBlue No. 1Consecutive adultsLaryngeal penetrationSwallow evaluationTracheal aspirationProspective studySpeech-language pathologistsLaryngeal vestibuleHigh intraIntrarater agreementTrialsBolus retentionInterrater reliabilityThree timesDysphagiaBolus flowAngiogenesis and lung cancer: prognostic and therapeutic implications.
Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal Of Clinical Oncology 2005, 23: 3243-56. PMID: 15886312, DOI: 10.1200/jco.2005.18.853.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorAntiangiogenic agentsLung cancerSurrogate markerProangiogenic vascular endothelial growth factorMajority of patientsReliable surrogate markerTumor vascular developmentDownstream receptor signalingKey therapeutic strategyEndothelial growth factorVEGF receptor bindingMetastatic diseaseMost patientsCancer deathConventional chemotherapyCommon causeTherapeutic strategiesTherapeutic implicationsTumor typesTumor vasculatureTarget inhibitionAnticancer effectsCytostatic effectReceptor signaling
1988
Intraventricular hemorrhage of the preterm neonate: prevention studies.
Ment L, Ehrenkranz R, Duncan C. Intraventricular hemorrhage of the preterm neonate: prevention studies. Seminars In Perinatology 1988, 12: 359-72. PMID: 3065945.Peer-Reviewed Original Research
1983
Contact hypersensitivity reactions to dinitrofluorobenzene mediated by monoclonal IgE anti-DNP antibodies.
Ray M, Tharp M, Sullivan T, Tigelaar R. Contact hypersensitivity reactions to dinitrofluorobenzene mediated by monoclonal IgE anti-DNP antibodies. The Journal Of Immunology 1983, 131: 1096-102. PMID: 6193174, DOI: 10.4049/jimmunol.131.3.1096.Peer-Reviewed Original ResearchConceptsContact hypersensitivity reactionHypersensitivity reactionsDNFB challengeUnsensitized controlsAntigen challengeReactive haptenMonoclonal IgE anti-DNP antibodyIgE anti-DNP antibodyIgE anti-hapten antibodyBALB/c miceAllergic contact dermatitis reactionsBiphasic patternIgE-sensitized miceEars of miceCutaneous hypersensitivity reactionsCutaneous hypersensitivity responseCutaneous inflammatory reactionsContact dermatitis reactionsFailure of miceAnti-hapten antibodiesAnti-DNP antibodiesEar challengeEar swellingHypersensitivity responseIgE antibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply